null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Anti-Mouse CTLA-4 [9D9] In Vivo Antibody - Ultra Low Endotoxin (IVMB0073)

SKU IVMB0073
Antibody Type Functional-Grade In Vivo Antibody
Applications In Vivo
Disease Area Cancer Immunotherapy
Disease Area Autoimmune Diseases
Clone 9D9
Protein CTLA-4
Isotype Mouse IgG2b
Reactivity Mouse
Synonyms CD152
Synonyms Cytotoxic T Lymphocyte-Associated Antigen-4
Synonyms Ly-56
Research Area Immune Checkpoint & Cancer Biology
Endotoxin Level Ultra Low Endotoxin
Host Species Mouse
Applications FA
Applications WB
€359 - €4,859
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altTechnical Datasheet

Anti-Mouse CTLA-4 [9D9] In Vivo Antibody - Ultra Low Endotoxin

Introducing the Anti-Mouse CTLA-4 [9D9] In Vivo Antibody - Ultra Low Endotoxin from Assay Genie, a specialized monoclonal antibody tailored for in vivo research. This antibody specifically targets the CTLA-4 protein, a critical regulator in immune checkpoint pathways, making it indispensable for studies in immunology, particularly those investigating immune response modulation and autoimmunity. With a rat IgG2b kappa isotype, this antibody ensures exceptional purity and ultra-low endotoxin levels (<0.001 EU/µg), making it ideal for sensitive applications such as ELISA, flow cytometry, functional assays, and in vivo experiments. Available in multiple sizes, it is formulated in a phosphate-buffered saline solution to maintain its stability and efficacy under experimental conditions.

Enhance the precision and reliability of your immunological research with the Anti-Mouse CTLA-4 [9D9] In Vivo Antibody from Assay Genie. CTLA-4 (Cytotoxic T-Lymphocyte-associated Protein 4) is a protein receptor that downregulates immune responses. CTLA-4 is predominantly expressed on the surface of T cells and plays a pivotal role in managing immune homeostasis and preventing autoimmune reactions. By targeting CTLA-4, researchers can explore novel therapeutic avenues in cancer immunotherapy and autoimmune disease management.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose